Alert detail
Proposed LCD DL40187: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Palmetto GBA
Policy ID: LCD-DL40187Specialty: GastroenterologyAdded: 6/5/2026lcd
What changed
New LCD for biomarker testing in liver disease proposed.
Who’s affected: Gastroenterology billing teams
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 12 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.